290 related articles for article (PubMed ID: 9331087)
1. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis.
Chiu CH; McEntee MF; Whelan J
Cancer Res; 1997 Oct; 57(19):4267-73. PubMed ID: 9331087
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice.
Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J
Cancer Res; 2002 Jan; 62(2):403-8. PubMed ID: 11809688
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis.
Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM
Cancer Res; 1996 Jun; 56(11):2556-60. PubMed ID: 8653697
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
5. Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Chiu CH; McEntee MF; Whelan J
Prostaglandins Leukot Essent Fatty Acids; 2000 May; 62(5):269-75. PubMed ID: 10883057
[TBL] [Abstract][Full Text] [Related]
6. R-flurbiprofen chemoprevention and treatment of intestinal adenomas in the APC(Min)/+ mouse model: implications for prophylaxis and treatment of colon cancer.
Wechter WJ; Kantoci D; Murray ED; Quiggle DD; Leipold DD; Gibson KM; McCracken JD
Cancer Res; 1997 Oct; 57(19):4316-24. PubMed ID: 9331093
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
8. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
9. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
10. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
11. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac.
Mahmoud NN; Bilinski RT; Churchill MR; Edelmann W; Kucherlapati R; Bertagnolli MM
Cancer Res; 1999 Jan; 59(2):353-9. PubMed ID: 9927046
[TBL] [Abstract][Full Text] [Related]
12. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.
Jacoby RF; Marshall DJ; Newton MA; Novakovic K; Tutsch K; Cole CE; Lubet RA; Kelloff GJ; Verma A; Moser AR; Dove WF
Cancer Res; 1996 Feb; 56(4):710-4. PubMed ID: 8631000
[TBL] [Abstract][Full Text] [Related]
14. [Treatment with sulindac of adenomatous polyps in familial polyposis].
Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis.
Perkins S; Verschoyle RD; Hill K; Parveen I; Threadgill MD; Sharma RA; Williams ML; Steward WP; Gescher AJ
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):535-40. PubMed ID: 12050094
[TBL] [Abstract][Full Text] [Related]
16. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
[TBL] [Abstract][Full Text] [Related]
17. Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac.
Bobe G; Wang B; Seeram NP; Nair MG; Bourquin LD
J Agric Food Chem; 2006 Dec; 54(25):9322-8. PubMed ID: 17147414
[TBL] [Abstract][Full Text] [Related]
18. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial chemoprevention of intestinal neoplasia.
Torrance CJ; Jackson PE; Montgomery E; Kinzler KW; Vogelstein B; Wissner A; Nunes M; Frost P; Discafani CM
Nat Med; 2000 Sep; 6(9):1024-8. PubMed ID: 10973323
[TBL] [Abstract][Full Text] [Related]
20. Relationship of beta-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice.
McEntee MF; Chiu CH; Whelan J
Carcinogenesis; 1999 Apr; 20(4):635-40. PubMed ID: 10223192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]